Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.71 |
| ▸ | TK1 | P04183 | 4/20 | 0.57 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | ALB | P02768 | 1/20 | 0.55 |
| ▸ | PKM | P14618 | 1/20 | 0.55 |
| ▸ | BLM | P54132 | 1/20 | 0.55 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | TK2 | O00142 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19407973 | 1.00 | RNASE1 (0.71) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL16287348 | 0.92 | RNASE1 (0.68) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL767324 | 0.92 | RNASE1 (0.68) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL14681227 | 0.92 | RNASE1 (0.68) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL774263 | 0.92 | RNASE1 (0.68) | RNASE1TK1SLC6A2LMNATSHR | |
| SCHEMBL16349867 | 0.92 | RNASE1 (0.71) | RNASE1TK1SLC6A2LMNAALB | |
| SCHEMBL13901238 | 0.92 | RNASE1 (0.71) | RNASE1TK1SLC6A2LMNAALB | |
| SCHEMBL25875139 | 0.88 | RNASE1 (0.55) | RNASE1TK1 | |
| SCHEMBL9397478 | 0.88 | TK1 (0.65) | RNASE1TK1 | |
| SCHEMBL8999382 | 0.87 | TK2 (0.67) | RNASE1TK1SLC6A2TK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4543960-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | Hongene Biotech Corporation (US) | 2025-04-30 | — | — | EP | disclosed |
| US-20250034192-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORP (US) | 2025-01-30 | — | — | US | disclosed |
| US-12134630-B2 | Compositions and methods for liquid phase oligonucleotide synthesis | HONGENE BIOTECH CORPORATION (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240002420-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION | 2024-01-04 | — | — | US | disclosed |
| WO-2023249905-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | HONGENE BIOTECH CORPORATION (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-1789460-B1 | POLYMERIC BEADS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS INC (US) | 2013-01-09 | — | — | EP | disclosed |
| US-7700706-B2 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2010-04-20 | — | — | US | disclosed |
| US-20090286085-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | US | disclosed |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | LSIS PHARMACEUTICALS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-7348391-B2 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| EP-1789460-A2 | POLYMERIC BEADS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2006029023-A2 | POLYMERIC BEADS FOR OLIGONUCLEOTIDE SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-16 | — | — | WO | disclosed |
| US-20060051800-A1 | Polymeric beads for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2006-03-09 | — | — | US | disclosed |
| US-6921636-B1 | Method and apparatus for conducting an array of chemical reactions on a support surface | METRIGEN, INC. (US) | 2005-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240002420-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLI, POLR2E | RNASE1 302/4885TK1 210/4885SLC6A2 3405/4885 |
| US-20090286085-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | RNASE1 4474/4885TK1 663/4885SLC6A2 4346/4885 |
| US-20250034192-A1 | COMPOSITIONS AND METHODS FOR LIQUID PHASE OLIGONUCLEOTIDE SYNTHESIS | POLR2H, POLI, POLR2E | RNASE1 302/4885TK1 210/4885SLC6A2 3405/4885 |
| US-20060051800-A1 | Polymeric beads for oligomer synthesis | NEFM, NOD2, MACF1 | RNASE1 4474/4885TK1 663/4885SLC6A2 4346/4885 |
| US-20080097028-A1 | POLYMERIC BEADS FOR OLIGOMER SYNTHESIS | NEFM, NOD2, MACF1 | RNASE1 4474/4885TK1 663/4885SLC6A2 4346/4885 |
| US-12134630-B2 | Compositions and methods for liquid phase oligonucleotide synthesis | POLR2H, POLI, POLR2E | RNASE1 302/4885TK1 210/4885SLC6A2 3405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.